Edition:
United States

Zosano Pharma Corp (ZSAN.OQ)

ZSAN.OQ on NASDAQ Stock Exchange Capital Market

4.69USD
3:59pm EST
Change (% chg)

$0.26 (+5.87%)
Prev Close
$4.43
Open
$4.52
Day's High
$4.69
Day's Low
$4.51
Volume
5,189
Avg. Vol
11,589
52-wk High
$63.40
52-wk Low
$3.63

Latest Key Developments (Source: Significant Developments)

Zosano Pharma Files Prospectus Related To 10 Mln Stock Offering
Tuesday, 6 Feb 2018 06:46am EST 

Feb 6 (Reuters) - Zosano Pharma Corp ::ZOSANO PHARMA CORP FILES PROSPECTUS RELATED TO OFFERING 10 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING‍​.  Full Article

Zosano Announces Resignation Of Bruce Steel From Board
Friday, 15 Dec 2017 04:30pm EST 

Dec 15 (Reuters) - Zosano Pharma Corp ::ZOSANO ANNOUNCES RESIGNATION OF BRUCE STEEL FROM BOARD OF DIRECTORS.ZOSANO PHARMA CORP - FOLLOWING STEEL'S RESIGNATION, NUMBER OF BOARD OF DIRECTOR SEATS HAS BEEN REDUCED TO FIVE.  Full Article

Zosano pharma Q3 loss per share $0.20
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Zosano Pharma Corp ::Zosano pharma reports third quarter 2017 financial results and operational update.Q3 loss per share $0.20.  Full Article

Zosano provides patent application update
Tuesday, 26 Sep 2017 05:02pm EDT 

Sept 26 (Reuters) - Zosano Pharma Corp :Zosano provides patent application update.Zosano Pharma Corp - Received official written notification of an office action from U.S. patent and trademark office.Zosano Pharma - Received notification regarding patent "method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines.".  Full Article

Zosano Pharma Q2 loss per share $0.17
Thursday, 10 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Zosano Pharma Corp :Zosano Pharma reports second quarter 2017 financial results and operational update.Q2 loss per share $0.17.  Full Article

Zosano Pharma announces outcome of end of phase 2 meetings with FDA
Monday, 26 Jun 2017 08:30am EDT 

June 26 (Reuters) - Zosano Pharma Corp :Zosano Pharma announces outcome of end of phase 2 meetings with FDA.Zosano Pharma - Received confirmation, a single efficacy study, our recently completed Zotrip trial, is sufficient to support an NDA filing for M207.Zosano Pharma - FDA concurred that development strategy, which conforms to relevant regulatory guidelines, appears adequate for registration of M207.Zosano Pharma Corp- Initiating long-term safety study in Q3 of 2017.  Full Article

Zosano Pharma appoints John Walker as interim CEO
Tuesday, 9 May 2017 04:00pm EDT 

May 9 (Reuters) - Zosano Pharma Corp :Zosano reports first quarter 2017 financial results and announces management changes.Q1 loss per share $0.34.Says John P. Walker appointed interim CEO.Zosano Pharma Corp - John P. Walker named interim chief executive officer to replace Konstantinos Alataris who has resigned as CEO.Zosano Pharma Corp - Georgia Erbez, chief business officer and interim chief financial officer, has assumed full responsibility for both functions.  Full Article

Zosano Pharma - on May 2, Winnie TSO, resigned as CFO
Friday, 5 May 2017 05:47pm EDT 

May 5 (Reuters) - Zosano Pharma Corp ::Zosano Pharma - on May 2, Winnie Tso, who has been on a medical leave of absence since may 13, 2016, resigned as cfo of co - sec filing.  Full Article

Zosano announces pricing of public offering of common stock
Friday, 17 Mar 2017 09:25am EDT 

Zosano Pharma Corp : Zosano announces pricing of public offering of common stock .Says public offering of 17.0 million common shares priced at $1.50 per share.  Full Article

Zosano Pharma Corp says prices common stock of 17 million shares at $1.50 per share
Friday, 17 Mar 2017 09:11am EDT 

Zosano Pharma Corp :Zosano Pharma Corp - prices common stock of 17 million shares at $1.50 per share.  Full Article

BRIEF-Zosano Pharma Files Prospectus Related Offering 12.5 Mln Shares

* ZOSANO PHARMA CORP FILES PROSPECTUS RELATED OFFERING 12.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING Source text: (http://bit.ly/2EDTBag) Further company coverage: